Spelling suggestions: "subject:"0.166"" "subject:"0,166""
1 |
The Role of Osteomacs in Regulating Stem Cell Function and the Hematopoietic NicheMohamad, Safa F. 02 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Maintenance of hematopoietic stem cell (HSC) function is an orchestrated event requiring the participation of multiple cell types within the hematopoietic niche. Among the key cellular components of the niche are a group of specialized bone-resident macrophages known as osteomacs (OM). Reported here is a detailed characterization of OM and description of discriminating phenotypic and functional properties that clearly distinguish OM from bone marrow-derived macrophages (BM Mφ). Furthermore, it was established that OM support hematopoiesis enhancing activity of osteoblasts and that this activity was augmented by megakaryocytes. Serial transplantation demonstrated that HSC repopulating potential was best maintained by in vitro cultures containing OM, osteoblasts and megakaryocytes. Interestingly, BM Mφ were unable to mediate the same hematopoiesis enhancing activity regardless of whether megakaryocytes were present in co-culture or not. Subsequently, to understand the importance of networking between the residents of the niche, 3D tissue cytometry was performed on fixed and stained unperturbed bone marrow sections. This approach identified the spatial relationships between OM, osteoblasts, megakaryocytes and HSC within the niche and defined parameters, under which these cell types coexist in undamaged bone marrow. In addition, single cell mRNAseq and CyTOF was performed to assess genetic and proteomic expression changes in OM following their interaction with megakaryocytes. These studies revealed the upregulation of CD166 and embigin on OM via osteoblast and megakaryocyte interactions. Clonogenic assays were conducted to examine the impact of these molecules in hematopoietic function. When these assays were initiated with CD166 KO OM or shRNA-mediated embigin knockdown OM, it was established that loss of these surface molecules on OM caused a decline in the normal OM-mediated hematopoietic enhancing activity. Conversely, recombinant CD166 and embigin partially substituted for OM activity thus identifying potential mediators through which OM maintain hematopoietic function. This data, for the first time, reveal intimate spatial interactions between OM, osteoblasts, megakaryocytes and HSC in the hematopoietic niche. They also illustrate the importance of crosstalk between OM, osteoblasts and megakaryocytes and reveal novel mediators such as CD166 and embigin that cooperate with other elements of the niche to support HSC function. / 2020-09-10
|
2 |
Identifizierung differenziell exprimierter Gene in soliden Tumoren am Beispiel des Prostatakarzinoms und der Einsatz ausgewählter Gene (CD24, CD166) als molekulare PrognosemarkerKristiansen, Glen 13 July 2004 (has links)
Durch Anwendung Array-basierter Transkriptanalyse auf mikrodissezierte Prostatagewebe konnten eine Vielzahl differenziell exprimierter Gene des Prostatakarzinoms identifiziert werden. Innerhalb dieser wurden CD166 und CD24 für die weiterführende Analyse ausgewählt. CD24 ist ein kleines Zelloberflächenmolekül, das ursprünglich in B-Zellen und malignen hämatologischen Erkrankungen beschrieben wurde. Eine CD24 Expression wurde auch in verschiedenen soliden Tumoren gefunden. Da CD24 ein Ligand von P-Selektin ist, könnte CD24 den Tumorzellen pro-metastatische Eigenschaften verleihen. Ziel der Studie war, die CD24 Expression in unseren Tumorkollektiven von Mamma- (n=201), Prostata- (n=102), Nicht-kleinzelligen Lungen- (n=89), Ovarial- (n=56) und Pankreaskarzinomen (n=95) immunhistologisch zu bestimmen. Diese Ergebnisse wurden mit klinisch-pathologischen Daten einschliesslich der Überlebensdaten korreliert. Die differenzielle Expression von CD166 wurde ebenfalls immunhistochemisch validiert. Eine CD24 Expression fand sich in 85% der Mammakarzinome, 48% der Prostatakarzinome, 45% der NSCLC, in 84% der Ovarialkarzinome und 72% der Pankreaskarzinome. CD24 Expression korrelierte univariat und multivariat signifikant (p / Applying array based transcript analysis to microdissected prostate tissues, a variety of differentially expressed genes of prostate cancer were identified. Among these, CD166 and CD24 were selected for further analysis. CD24 is a small cell surface molecule that has originally been described in B-cells and hematologic malignancies. Expression of CD24 was also found in various solid tumours. Being a ligand of P-selectin, CD24 might confer pro-metastatic properties to tumour cells. We aimed to clarify the expression of CD24 in our collectives of breast cancer (n=201), prostate cancer (n=102), non-small cell lung cancer (NSCLC, n=89), epithelial ovarian cancer (EOC, n=56) and pancreatic cancer (n=95) by immunohistochemistry. These results were correlated to clinicopathological parameters including survival data. The differential expression of CD166 was validated immunohistochemically as well. Expression of CD24 was found in 85% of breast cancer, 48% of prostate cancer, 45% of NSCLC, 84% of EOC and 72% of pancreatic cancer. CD24 expression correlated significantly (p
|
3 |
CD166 modulates disease progression and osteolytic disease in multiple myelomaXu, Linlin 16 March 2016 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Multiple myeloma (MM) is an incurable malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow (BM) and by multiple osteolytic lesions throughout the skeleton. We previously reported that CD166 is a functional molecule on normal hematopoietic stem cells (HSC) that plays a critical role in HSC homing and engraftment, suggesting that CD166 is involved in HSC trafficking and lodgment. CD166, a member of the immunoglobulin superfamily capable of mediating homophilic interactions, has been shown to enhance metastasis and invasion in several tumors. However, whether CD166 is involved in MM and plays a role in MM progression has not been addressed. We demonstrated that a fraction of all human MM cell lines tested and MM patients’ BM CD138+ cells express CD166. Additionally, CD166+ cells preferentially home to the BM of NSG mice. Knocking-down (KD) CD166 expression on MM cells with shRNA reduced their homing to the BM. Furthermore, in a long-term xenograft model, NSG mice inoculated with CD166KD cells showed delayed disease progression and prolonged survival compared to mice receiving mock transduced cells. To examine the potential role of CD166 in osteolytic lesions, we first used a novel Ex Vivo Organ Culture Assay (EVOCA) which creates an in vitro 3D system for the interaction of MM cells with the bone microenvironment.
EVOCA data from MM cells lines as well as from primary MM patients’ CD138+ BM cells demonstrated that bone osteolytic resorption was significantly reduced when CD166 was absent on MM cells or calvarial cells. We then confirmed our ex vivo findings with intra-tibial inoculation of MM cells in vivo. Mice inoculated with CD166KD cells had significantly less osteolytic lesions. Further analysis demonstrated that CD166 expression on MM cells alters bone remodeling by inhibiting RUNX2 gene expression in osteoblast precursors and increasing RANKL to OPG ratio in osteoclast precursors. We also identified that CD166 is indispensable for osteoclastogenesis via the activation of TRAF6-dependent signaling pathways. These results suggest that CD166 directs MM cell homing to the BM and promotes MM disease progression and osteolytic disease. CD166 may serve as a therapeutic target in the treatment of MM.
|
4 |
Impact of ALCAM (CD166) on homing of hematopoietic stem and progenitor cellsAleksandrova, Mariya Aleksandrova 18 December 2012 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / The potential of hematopoietic stem cells (HSC) to home and to anchor within the bone marrow (BM) microenvironment controls the ability of transplanted HSCs to establish normal hematopoiesis. Activated Leukocyte Cell Adhesion Molecule (ALCAM; also identified as CD166), which participates in homophilic interactions, is expressed on a group of osteoblasts in the hematopoietic niche capable of sustaining functional HSC in vitro. Since we could also detect ALCAM expression on HSC, we suspect that ALCAM may play a role in anchoring primitive hematopoietic cells to ALCAM expressing components of the hematopoietic niche via dimerization. We investigated the role of ALCAM on the homing abilities of hematopoietic stem and progenitor cells (HSPC) by calculating recovery frequency of Sca-1+ALCAM+ cells in an in vivo murine bone marrow transplantation model. Our data supports the notion that ALCAM promotes improved homing potential of hematopoietic Sca-1+ cells. Recovery of BM-homed Sca-1+ cells from the endosteal region was 1.8-fold higher than that of total donor cells. However, a 3.0-fold higher number of Sca-1+ALCAM+ cells homed to the endosteal region compared to total donor cells. Similarly, homed Sca-1+ALCAM+ cells were recovered from the vascular region at 2.1-fold greater frequency than total homed donor cells from that region, compared to only a 1.3-fold increase in the recovery frequency of Sca-1+ cells. In vitro quantitation of clonogenic BM-homed hematopoietic progenitors corroborate the results from the homing assay. The frequency of in vitro clonogenic progenitors was significantly higher among endosteal-homed Sca-1+ALCAM+ cells compared to other fractions of donor cells. Collectively, these data demonstrate that engrafting HSC expressing ALCAM home more efficiently to the BM and within the BM microenvironment, these cells preferentially seed the endosteal niche.
|
Page generated in 0.0187 seconds